Should decisions on adding adjuvant chemotherapy in early-stage ER-positive breast cancer be based on gene expression testing or clinicopathologic factors or both?

D. B. Geffen

Research output: Contribution to journalEditorial

3 Scopus citations
Original languageEnglish
Pages (from-to)1096-1098
Number of pages3
JournalAnnals of Oncology
Volume29
Issue number5
DOIs
StatePublished - 1 May 2018
Externally publishedYes

Cite this